Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PSMA CAR NK Cells in mCRPC
NCT03692663Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Dec 2018
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events as assessed by CTCAE v5.0 at 1 year. Status: unknown.
02
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03692663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692663.